phenylmethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate | 778642-39-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylmethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate
• 英文别名: phenylmethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1 (2H)-pyridinecarboxylate；benzyl 4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 778642-39-0
• 化学式: C₂₇H₃₄N₂O₃
• 分子量: 434.579
• InChiKey: RMPIXAOAKSZBEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  phenylmethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate 在 钯 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以to afford the title compound (3.51 g, 98%)的产率得到1-(1-methylethyl)-4-{[4-(4-piperidinyl)phenyl]oxy}piperidine
  参考文献：
  名称：

  4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's

  摘要：

  本发明涉及具有药理活性的新型苯基哌啶衍生物，其制备过程，含有它们的组合物以及它们在神经和精神障碍治疗中的应用。

  公开号：

  US20060205774A1
• 作为产物：
  描述：

  4-[4-(4-piperidinyloxy)phenyl]-3,6-dihydro-1(2H)-pyridinecarboxylate 、 丙酮 在 三乙酰氧基硼氢化钠 、 sodium hydroxide 作用下， 以 二氯甲烷 、 溶剂黄146 、 水 为溶剂， 反应 18.17h， 以93%的产率得到phenylmethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate
  参考文献：
  名称：

  [EN] 4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S
  [FR] DERIVES DE 4-(4-(HETEROCYCLYLALKOXY)PHENYL-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE ET COMPOSES ASSOCIES SERVANT D'ANTAGONISTES D'HISTAMINE H3 DESTINES AU TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  本发明在第一方面提供了一个式(I)的化合物或其药学上可接受的盐，其中：R1代表-C1-6烷基-O-C1-6烷基，-C3-8环烷基，芳基，杂环烷基，杂芳基和其他基团；X代表键，O，CO，OCH2，CH2O或SO2；Z代表CO，CONR10或SO2；R10代表氢，C1-6烷基，-C3-8环烷基，芳基，杂环烷基，杂芳基；A代表单键或双键；m和n独立地代表0，1或2；R2代表氢，C1-6烷基或C1-6烷氧基；R3代表卤素，C1-6烷基，羟基，C1-6烷氧基，氰基，氨基，-COC1-6烷基，-SO2C1-6烷基或三氟甲基；R4代表-(CH2)q-NR11R12或一个式(i)的基团，其中所有其他取代基的定义如权利要求1所述。式(I)的化合物及其药学上可接受的盐具有亲和力，并且是组织胺H3受体的拮抗剂和/或逆向激动剂，被认为在治疗包括阿尔茨海默病在内的神经系统疾病中具有潜在用途。

  公开号：

  WO2004089373A1

文献信息

• 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S
  申请人：GLAXO GROUP LIMITED

  公开号：EP1610786B1

  公开（公告）日：2007-06-20
• [EN] 4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S<br/>[FR] DERIVES DE 4-(4-(HETEROCYCLYLALKOXY)PHENYL-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE ET COMPOSES ASSOCIES SERVANT D'ANTAGONISTES D'HISTAMINE H3 DESTINES AU TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004089373A1

  公开（公告）日：2004-10-21

  The present invention provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: R1 represents -C1-6 alkyl-O-C1-6 alkyl, -C3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl and other groups; X represents a bond, O, CO, OCH2, CH2O or SO2; Z represents CO, CONR10 or SO2; R10 represents hydrogen, C1-6 alkyl, -C3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl; A represents a single or a double bond; m and n independently represent 0, 1 or 2; R2 represents hydrogen, C1-6 alkyl or C1-6 alkoxy; R3 represents halogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, cyano, amino, -COC1-6 alkyl, -SO2C1-6 alkyl or trifluoromethyl; R4 represents -(CH2)q-NR11R12 or a group of formula (i) wherein all the other substituents are as defined in claim 1. Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease.

  本发明在第一方面提供了一个式(I)的化合物或其药学上可接受的盐，其中：R1代表-C1-6烷基-O-C1-6烷基，-C3-8环烷基，芳基，杂环烷基，杂芳基和其他基团；X代表键，O，CO，OCH2，CH2O或SO2；Z代表CO，CONR10或SO2；R10代表氢，C1-6烷基，-C3-8环烷基，芳基，杂环烷基，杂芳基；A代表单键或双键；m和n独立地代表0，1或2；R2代表氢，C1-6烷基或C1-6烷氧基；R3代表卤素，C1-6烷基，羟基，C1-6烷氧基，氰基，氨基，-COC1-6烷基，-SO2C1-6烷基或三氟甲基；R4代表-(CH2)q-NR11R12或一个式(i)的基团，其中所有其他取代基的定义如权利要求1所述。式(I)的化合物及其药学上可接受的盐具有亲和力，并且是组织胺H3受体的拮抗剂和/或逆向激动剂，被认为在治疗包括阿尔茨海默病在内的神经系统疾病中具有潜在用途。
• 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's
  申请人：Bamford James Mark

  公开号：US20060205774A1

  公开（公告）日：2006-09-14

  The present invention relates to novel phenyl piperidinyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型苯基哌啶衍生物，其制备过程，含有它们的组合物以及它们在神经和精神障碍治疗中的应用。